| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/07/2004 | CN1144787C Aryl fused azapolycyclic compounds |
| 04/07/2004 | CN1144785C Hydroxamic acid and its preparation, and pharmaceutical composition |
| 04/07/2004 | CN1144598C Stabilization of compositions containing ACE inhibitors using magnesium oxide |
| 04/07/2004 | CN1144593C Reagent for diagnosing early urinary culculus |
| 04/07/2004 | CN1144587C Agents for relieving side effects |
| 04/07/2004 | CN1144585C Animal fast biochemical accelerating composition containing cysteamine and its salt and use |
| 04/06/2004 | US6717030 Diploid animal cell for use in the treatment of drug addiction, epilepsey, withdrawal syndrome and muscle spasm |
| 04/06/2004 | US6716985 Alcoholism, psychological disorders |
| 04/06/2004 | US6716880 Function as sulfatase and/or blocking estrogen receptors; prophylaxis and therapy |
| 04/06/2004 | US6716871 Cyclic AMP-specific phosphodie sterase inhibitors |
| 04/06/2004 | US6716870 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 04/06/2004 | US6716869 N-(2-(1-amidinopyrrol-3-yl)ethyl)-5,6-dihydroxy-1-(2-(2-methox y-3-sulfatopropionylamino)-3-chloro-4-methylvaleroyl)indole-2-carboxamide |
| 04/06/2004 | US6716868 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 04/06/2004 | US6716865 Benzoxa- and benzthiazoles |
| 04/06/2004 | US6716856 Cell proliferative disorders or alzheimer's disease; reduced toxicity; cdk/cyclin kinase inhibitory activity |
| 04/06/2004 | US6716855 Antithrombotic amides |
| 04/06/2004 | US6716852 Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors |
| 04/06/2004 | US6716850 Non-nucleoside reverse transcriptase inhibitors |
| 04/06/2004 | US6716849 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 04/06/2004 | US6716846 High affinity ligands for nociceptin receptor ORL-1 |
| 04/06/2004 | US6716845 Barbituric acid derivatives |
| 04/06/2004 | US6716843 Inhibitor of dipeptidyl-peptidase iv |
| 04/06/2004 | US6716841 Nitrogen containing heterobicycles as factor Xa inhibitors |
| 04/06/2004 | US6716840 Agonists of the melanocortin-4 receptor (?mc-4r?); useful treating obesity and type 2 diabetes |
| 04/06/2004 | US6716839 Inhibitor of factor xa |
| 04/06/2004 | US6716837 Heterocyclic compounds for the treatment of migraine |
| 04/06/2004 | US6716836 Non-nucleoside reverse transcriptase inhibitors |
| 04/06/2004 | US6716834 Thiochromane derivatives and their use as thrombin inhibitors |
| 04/06/2004 | US6716831 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity |
| 04/06/2004 | US6716825 Osteoporosis and other disorders of bone metabolisum, cancer, viral infections, and the like. |
| 04/06/2004 | US6716822 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition |
| 04/06/2004 | US6716818 Caspase inhibitors and the use thereof |
| 04/06/2004 | US6716624 GSK3 polypeptides |
| 04/06/2004 | US6716603 Nucleic acids encoding a chloride channel protein |
| 04/06/2004 | US6716430 Moderating immunology response |
| 04/06/2004 | US6716417 Condensation of heated vapor to form aerosol particles |
| 04/06/2004 | US6716416 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of an antipsychotic such as olanzapine, trifluoperazine, haloperidol, loxapine, clozapine, quetiapine, promazine, etc. |
| 04/06/2004 | US6716415 An aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of a sedative-hypnotic, such as zaleplon, zolpidem or zopiclone. |
| 04/06/2004 | CA2404810C Topical composition having undifferentiated plant seed cells and method for using same |
| 04/06/2004 | CA2299399C Benzenesulfonamide inhibitors of pde-iv and their therapeutic use |
| 04/06/2004 | CA2269077C Keratinocyte growth factor-2 products |
| 04/06/2004 | CA2089563C Oligonucleotide modulation of cell adhesion |
| 04/06/2004 | CA2075926C Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them |
| 04/06/2004 | CA2060616C Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers |
| 04/06/2004 | CA2036592C Therapeutic agent for diabetic gangrene |
| 04/01/2004 | WO2004026874A1 Novel crystals of triazaspiro[5.5]undecane derivative |
| 04/01/2004 | WO2004026873A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| 04/01/2004 | WO2004026861A1 Process for producing paroxetine hydrochloride hydrate |
| 04/01/2004 | WO2004026841A1 Novel 6-substituted uracil derivative and therapeutic agent for allergic disease |
| 04/01/2004 | WO2004026833A1 Cyclic amine compound, process for producing the same, and use |
| 04/01/2004 | WO2004026832A1 Urea compound and use thereof |
| 04/01/2004 | WO2004026831A1 2,4-substituted indoles and their use as 5-ht6 modulators |
| 04/01/2004 | WO2004026829A2 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors |
| 04/01/2004 | WO2004026816A1 Aromatic liver x-receptor modulators |
| 04/01/2004 | WO2004026815A2 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | WO2004026343A1 Site-specific gene conversion promoter and gene therapeutic |
| 04/01/2004 | WO2004026342A1 AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING |
| 04/01/2004 | WO2004026341A1 Immunotherapeutic for cancer |
| 04/01/2004 | WO2004026324A1 Antiallergic agent and antiinflammatory agent |
| 04/01/2004 | WO2004026317A1 Histamine release inhibitor |
| 04/01/2004 | WO2004026297A1 Preparation for external use |
| 04/01/2004 | WO2004026296A1 Composition against stress-related diseases |
| 04/01/2004 | WO2004026116A2 Use of etodoclac to treat hyperplasia |
| 04/01/2004 | WO2004009762A9 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 04/01/2004 | WO2004009123A3 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/01/2004 | WO2004007723A3 Genes |
| 04/01/2004 | WO2004005478A3 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 04/01/2004 | WO2003106659A3 Aptamer-toxin molecules and methods for using same |
| 04/01/2004 | WO2003106425A3 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 04/01/2004 | WO2003104443A3 Hair follicle mesenchymal stem cells and use thereof |
| 04/01/2004 | WO2003101932A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 04/01/2004 | WO2003099819A3 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics |
| 04/01/2004 | WO2003099771A3 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003097658A3 Compounds and methods for inhibiting selectin-mediated function |
| 04/01/2004 | WO2003097633A8 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 04/01/2004 | WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands |
| 04/01/2004 | WO2003088927A3 Novel curcumin analogues and uses thereof |
| 04/01/2004 | WO2003084540A3 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 04/01/2004 | WO2003084343A3 Method and dietary composition for improving fat digestibility |
| 04/01/2004 | WO2003082926A3 Antimicrobial polymer conjugates |
| 04/01/2004 | WO2003077893A3 Compositions for treating digestive functional pathologies |
| 04/01/2004 | WO2003072821A3 Method and nucleic acids for the analysis of a colon cell proliferactive disorder |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003068148A3 Treatment of sleep disorders using sleep target modulators |
| 04/01/2004 | WO2003063792A3 Compositions and methods related to tim-3, a th1-specific cell surface molecule |
| 04/01/2004 | WO2003060090A3 Novel cytokine zcytor17 ligand |
| 04/01/2004 | WO2003059874A3 Aromatic thioether liver x-receptor modulators |
| 04/01/2004 | WO2003028692A8 Acne treatment using oleanolic acid |
| 04/01/2004 | WO2003025019A8 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 04/01/2004 | WO2003016563A3 Novel molecular target for neurotoxicity |
| 04/01/2004 | WO2003014161A9 Antigen binding domains from fish |
| 04/01/2004 | WO2003009842A8 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/01/2004 | WO2002102314A3 Purine inhibitors of phosphodiesterase (pde) 7 |
| 04/01/2004 | WO2002098852A8 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins |
| 04/01/2004 | WO2002092758A3 Gastrokines and derived peptides including inhibitors |
| 04/01/2004 | WO2002085897A9 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 04/01/2004 | WO2002083847A3 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2004 | WO2002076402A3 Fatty amine drug conjugates |